comparemela.com
Home
Live Updates
UCB : receives European Commission approval for BIMZELX▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa : comparemela.com
UCB : receives European Commission approval for BIMZELX▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa
UCB receives European Commission approval for BIMZELX[®]▼ as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa
...
Related Keywords
Germany ,
Ireland ,
Brussels ,
Bruxelles Capitale ,
Belgium ,
Eimear Obrien ,
Antje Witte ,
Klinikum Dessau ,
Laurent Schots ,
Barry Mcgrath ,
Emmanuel Caeymaex ,
J Clin Pharmacol ,
Corporate Communications ,
Immunology Solutions ,
Brandenburg Medical School ,
Brand Communications ,
European Union ,
European Commission ,
European Hidradenitis Suppurativa Foundation ,
Twitter ,
Medicinal Products ,
Human Use ,
European Medicines ,
Executive Vice President ,
Important Safety ,
Euronext Brussels ,
Rev Dis ,
Markets ,
comparemela.com © 2020. All Rights Reserved.